pSivida Corp. announced that they have teamed up with a Biopharmaceutical company to evaluate their Tethadur technology. Tethadur is a protein and antibody delivery method for treating diseases that occur in the back of the eye. Though the pharmaceutical company has not been named pSivida’s CEO Dr. Paul Ashton assures that it is a ‘global leader’. "A sustained delivery system for these types of molecules would offer a significant clinical advance in the ophthalmic area where injections of protein based drugs into the eye every one or two months are sometimes required," Ashton said.
Tethadur utilizes an injectable, bioerodible, nanostructured, porous BioSilicon material for drug delivery. The sizes of thepores in the BioSilicon material are manufactured using nanotechnology to accommodate specific protein, peptide or antibody molecules that are then released on a sustained basis over time as the material bioerodes. pSividia's marketing partner Alimera is raising money in Europe to launch a product, Iluvien, which uses a similar platform.
Could all of these developments impact the microneedle research that has recently been done at Georgia Institute of Technology and Emory University? Will this change the way eye medication is administered?
At Drug Delivery Partnerships, hundreds of pharmaceutical and drug delivery thought leaders come together to develop partnerships to create the next great product that will bring relief to millions of patients. Sign up for updates on the 17th Annual Drug Delivery Partnerships Conference taking place February 6-8, 2012, in San Diego, CA.